0.40
+0.005(+1.28%)
Currency In USD
| Previous Close | 0.39 |
| Open | 0.4 |
| Day High | 0.43 |
| Day Low | 0.39 |
| 52-Week High | 2.17 |
| 52-Week Low | 0.3 |
| Volume | 718,122 |
| Average Volume | 1.28M |
| Market Cap | 29.65M |
| PE | -0.25 |
| EPS | -1.53 |
| Moving Average 50 Days | 0.44 |
| Moving Average 200 Days | 0.64 |
| Change | 0 |
If you invested $1000 in Beyond Air, Inc. (XAIR) since IPO date, it would be worth $132.2 as of February 05, 2025 at a share price of $0.39. Whereas If you bought $1000 worth of Beyond Air, Inc. (XAIR) shares 5 years ago, it would be worth $65.66 as of February 05, 2025 at a share price of $0.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
GlobeNewswire Inc.
2 hours ago
GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast
GlobeNewswire Inc.
Jan 27, 2025 9:05 PM GMT
GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th
Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia
GlobeNewswire Inc.
Jan 24, 2025 2:15 PM GMT
GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th